Panobacumab

Panobacumab is a monoclonal antibody designed for the treatment of infections caused by the bacterium Pseudomonas aeruginosa. It was developed by Arpida, a Swiss biopharmaceutical company.

Mechanism of action

Panobacumab works by binding to the O-polysaccharide part of the lipopolysaccharide (LPS) on the outer membrane of P. aeruginosa. This binding action inhibits the bacterium's ability to cause infection.

Clinical trials

Panobacumab has undergone Phase II clinical trials for the treatment of P. aeruginosa infections in patients with ventilator-associated pneumonia (VAP). However, as of 2021, it has not been approved for use by any major regulatory authority.

See also

• List of monoclonal antibodies
• Pseudomonas aeruginosa
• Ventilator-associated pneumonia

References

Panobacumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski